SEC Form 4 · accession 0001104659-17-037755
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew I Koven
Officer — President & Chief Business Off
Period of report
Jun 5, 2017
Accepted (ET)
Jun 6, 2017 · 8:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | Jun 5, 2017 | S | 161,906 | $1.2792 | D | 1,363,695 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents shares sold by the issuer on behalf of the reporting person for payment of withholding tax liability incurred upon the vesting of 369,169 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $1.2700 to $1.2900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.